For example, phase 2 Lung-MAP (NCT05364645) investigates carboplatin and pemetrexed with or without selpercatinib in patients with RET fusion-positive recurrent or metastatic NSCLC. The gene discussed is RET; the disease is non-small cell lung carcinoma.